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Disruptions in iron homeostasis are linked to a broad spectrum of chronic conditions
including cardiovascular, malignant, metabolic, and neurodegenerative disease. Evidence
supporting this contention derives from a variety of analytical approaches, ranging from
molecular to population-based studies.This review focuses on key epidemiological studies
that assess the relationship between body iron status and chronic diseases, with particular
emphasis on atherosclerosis ,metabolic syndrome and diabetes. Multiple surrogates have
been used to measure body iron status, including serum ferritin, transferrin saturation,
serum iron, and dietary iron intake. The lack of a uniform and standardized means of
assessing body iron status has limited the precision of epidemiological associations.
Intervention studies using depletion of iron to alter risk have been conducted. Genetic
and molecular techniques have helped to explicate the biochemistry of iron metabolism at
the molecular level. Plausible explanations for how iron contributes to the pathogenesis
of these chronic diseases are beginning to be elucidated. Most evidence supports the
hypothesis that excess iron contributes to chronic disease by fostering excess production
of free radicals. Overall, epidemiological studies, reinforced by basic science experiments,
provide a strong line of evidence supporting the association between iron and elevated risk
of cardiovascular disease and diabetes. In this narrative review we attempt to condense
the information from existing literature on this topic.
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INTRODUCTION
Cardiovascular disease (CVD) and diabetes aremajor health prob-
lems worldwide. In the United States, approximately one in four
deaths are due to heart disease, making it the leading cause of
death for both men and women (Heron et al., 2009; Heidenreich
et al., 2011)1. Coronary heart disease is the most common type
of heart disease, and costs the US over 100 billion each year (Go
et al., 2013). Risk factors include high blood pressure, high LDL
cholesterol, smoking, diabetes, and obesity (MMWRMorbMortal
Wkly Rep 60, 2001). Diabetes is itself a signiﬁcant health problem
that is reaching epidemic proportions, with a global prevalence of
382 million people in 2013. It is estimated that by 2035 this will
rise to 592 million2.
The search for risk factors and methods of prevention for both
CVD and diabetes are major efforts of the medical and research
community. The role of iron as a risk factor for CVD and diabetes
has drawn attention in part due to the concept that it may be a risk
factor susceptible to simple dietary modiﬁcation. Although this is
an oversimpliﬁcation, many (not all) reports suggest that there is
indeed an association between iron and both CVD and diabetes,
as detailed in this review.
1http://www.cdc.gov/heartdisease/facts.htm (accessed February 2, 2014).
2http://www.idf.org/diabetesatlas
Epidemiological studies have been a powerful tool to probe the
association between iron and CVD and diabetes. Several types of
study design have been employed. Each of these has its beneﬁts and
limitations. Brieﬂy, epidemiological studies can be divided into
observational and experimental studies. The difference between
an observation and experimental study is that in the latter, an
outcome is studied in a population in the absence or presence
of an intervention by the investigator. In an observational study,
there is no intervention and the investigator simply “observes”
and analyses the relationship between exposure and disease out-
come. Observational studies include cohort studies, case-control
studies and cross sectional studies. A cohort study is an analysis
of risk factors where a disease-free study population is identiﬁed
and followed prospectively over time and a subsequent evalua-
tion is done to ﬁnd the association between the exposure and
disease outcome. While this kind of study can provide strong
scientiﬁc evidence of an association between risk factors and dis-
ease and a temporal framework to assess causality, it is limited
by the requirement for a large sample size and long follow-up
duration. Often several biases can adulterate the evidence. A
case control study on the other hand starts with groups with
and without an outcome and evaluates how much a suspected
exposure might have contributed to the present outcome status.
Thus in comparison to cohort studies, case control studies are
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relatively quicker to conduct, inexpensive and require compara-
tively fewer subjects. Cross sectional studies collect and analyze
the data on exposure and disease at one speciﬁc time point. Such
studies cannot evaluate cause and effect relationships since there
is no temporal assessment. Table 1 shows the level of evidence
of different types of epidemiological studies. In the hierarchy of
evidence-based medicine, experimental studies (or more specif-
ically randomized controlled trials) are recognized as level I of
scientiﬁc evidence. However, the consensus over this has recently
changed as observational studies have been reported to be as effec-
tive as randomized controlled trials in estimating the impact of
medical interventions on disease outcomes (Benson and Hartz,
2000; Concato et al., 2000). Of course, it must also be emphasized
that for a potential hazard, such as elevated body iron, a ran-
domized controlled trials cannot be performed ethically, although
it could be done for a study of iron reduction by, for example,
phlebotomy.
Virtually all of these epidemiological analyses have been used to
probe the relationship between iron andCVDordiabetes. PubMed
searches using the terms “iron heart disease epidemiology” or
“iron diabetes epidemiology” identify over 500 papers for each
search term. In this narrative review, we have not attempted to be
comprehensive, but to focus on key epidemiological studies that
have investigated these issues. We provide some historical context,
but emphasize recent, well-controlled studies with large sample
size.
IRON AND CARDIOVASCULAR DISEASE
Cardiovascular disease is a broad term that includes ischemic and
non-ischemic irregularities. Associationwith iron has beenmainly
studied and found in ischemic cardiovascular diseases caused by
atherosclerosis. To measure ischemic disease outcome, several dif-
ferent endpoints have been used, including coronary heart disease
(CHD), carotid artery plaque formation, coronary artery calcium
deposition, carotid intima thickness, and atherosclerosis. CHDhas
been measured by myocardial infarction and cardiogenic angina
occurrences and deaths from such incidents. The role of iron in
CVD has generally been explored in a group of individuals using
one of these deﬁned endpoints. For the purposes of this review,
we have included all of these clinical entities under the umbrella
of CVD and have not attempted to differentiate among them.
The most common measurement used in the assessment of
body iron has been serum ferritin. Serum ferritin was shown
to correlate with body iron stores in the 1970s, and is still used
clinically for this purpose (Jacobs et al., 1972; Cook et al., 1974;
Jacobs and Worwood, 1975; Wang et al., 2010). However, serum
ferritin can also be elevated by acute and chronic inﬂammation
(Wang et al., 2010). Accounting for the contribution of these vari-
ables thus becomes an important component of studies that use
serum ferritin as a measure of body iron, as discussed below.
Less frequently, the ratio of soluble transferrin receptor to fer-
ritin has been used, as it has been suggested that this is a more
precise measure for body iron store than ferritin alone (Skikne
et al., 1990). Catalytically available iron has also been measured
in some studies, with the goal of measuring reactive rather than
total iron. This approach derives from the consideration that the
preponderance of iron in the body is bound to proteins and is not
available for participation in the potentially deleterious reactions
that are thought to underlie much of the toxicity of iron, such
as the formation of reactive oxygen species. A limitation of this
approach is that since catalytically available iron represents a rel-
atively small fraction of total iron, its measurement is technically
challenging.
The hypothesis that iron status could inﬂuence the risk of coro-
nary heart disease was ﬁrst proposed by Sullivan in the 1980s.
Sullivan hypothesized that the higher occurrence of CHD in men
and post-menopausal women than in pre-menopausal women
was due to higher iron stores in them compared to menstruat-
ing women (Sullivan, 1981, 1989). Some earlier studies supported
the hypothesis. In a cohort of 2873 Framingham women, an
increase in incidence of CHD and disease severity was observed
in women who had either natural or surgical menopause (Gordon
et al., 1978). In some early prospective studies, a weak associa-
tion between high blood hemoglobin and hematocrit and risk
of CHD was noted (Cullen et al., 1981; Bottiger and Carlson,
1982; Knottnerus et al., 1988). Hemoglobin and hematocrit are
not good surrogates for body iron status and during this period
serum ferritin was emerging as the best measurement of body
iron status (Cook et al., 1974; Kaltwasser and Werner, 1989). The
ﬁrst report in humans on the association between serum ferritin
and CHD risk was published in Salonen et al. (1992a). In this
cohort of randomly selected 1931 Eastern Finnish men, serum
ferritin concentration had a signiﬁcant association with ischemic
heart disease risk. Subjects with serum ferritin ≥200 μg/l had a
2.2-fold (95% CI, 1.2–4.0; p < 0.01) higher risk of acute myocar-
dial infarction compared to men with lower serum ferritin. Total
blood leucocyte countwas adjusted in the statistical analysis to rule
out the potential confounding effect of inﬂammation or chronic
Table 1 | Evidence level provided by epidemiological studies of different design.
Level of evidence Qualifying studies
I High quality, multicenter or single center, randomized controlled trial with adequate power: or systemic review of these studies
II Lesser quality, randomized controlled trial; prospective cohort study; or systemic review of these studies
III Retrospective comparative study; case-control study; or systemic review of these studies
IV Case series
V Expert opinion; case report or clinical example; or evidence based on physiology, bench research, or “ﬁrst principles”
Song and Chung (2010).
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vascular disease that would elevate serum ferritin independent of
body iron status. The association was stronger in men with higher
concentrations of low density lipoproteins (RR = 1.8, 95% CI,
0.9–3.5, NS in men with low LDL and a RR = 4.7, 95% CI,
1.4–16.3, p < 0.05 in men with high LDL). After this report,
the group conducted another nested case-control study within
the Kuopio Ischemic Heart Disease Risk Factor Study (KIHD)
cohort and found that men with high body iron stores were at
increased risk of acute myocardial infarction (AMI), conﬁrming
their original observation (Tuomainen et al., 1998). In this study
body iron status was measured by ratio of soluble TfR and fer-
ritin which some authors suggest as a better measure of body
iron than serum ferritin alone (Cook et al., 1974; Skikne et al.,
1990).
The ﬁrst prospective study in women was conducted in 11,471
Dutch post-menopausal female subjects aged 49–70 years (van
der et al., 2005). In the study, the multivariate hazard ratio of
ischemic strokes in the highest tertile of serum ferritin concentra-
tion was 2.23(95% CI, 1.05–4.73) compared to the lowest. An
interesting ﬁnding common to some of these studies was the
interaction of LDL with serum ferritin in increasing the risk of
ischemic events. A plausible biological mechanism underlying this
interaction may be the ability of iron to produce reactive oxygen
species. Iron catalyzes the Fenton reaction which produces potent
oxidants that increase the risk of atherosclerosis by promoting
the peroxidation of lipids (McCord, 1991; Salonen et al., 1992b;
Berliner and Heinecke, 1996). Local release of iron from ferritin
by superoxide radical generated by ischemia/reperfusion injury to
blood vessels may further exacerbate this damage (Thomas et al.,
1985).
Many of the studies discussed above focused on cardiovascular
events such as acute myocardial infarction. However, myocardial
infarction is a complex endpoint resulting from multiple poten-
tial pathogenesis pathways. To circumvent this limitation, other
studies used preclinical atherosclerosis as the dependent vari-
able and explored its relationship to serum ferritin. For example,
Kiechl et al. (1997) reported that serum ferritin level was closely
related to incidence of carotid atherosclerosis and progression of
previous atherosclerotic lesions in a cohort of Italian men and
women. In a cross sectional study that included German men and
women, there was an association of serum ferritin with carotid
plaque prevalence in both men (OR: 1.33; 95% CI, 1.08–1.44) and
women (OR, 1.29; 95% CI, 0.98–1.75) (Wolff et al., 2004). When
the study population was divided into ferritin octiles, both men
andwomen showed a dose-dependent relationship between serum
ferritin and atherosclerotic plaques. Subjects with malignancy
and liver diseases were excluded to eliminate the confounding
effect of inﬂammation and mild liver disease, but no adjust-
ments were made for any inﬂammatory markers. Thus, acute or
chronic inﬂammatory conditions could have confounded the ﬁnd-
ings in this study by affecting serum ferritin levels at the time of
measurement.
Several recent studies have shown that serum ferritin is inde-
pendently associated with preclinical measures of vascular dis-
eases. Sung et al. (2012) showed that ferritin levels in a large cohort
of 12,033 young Korean men were independently associated with
coronary artery calcium content, amarker of early coronary artery
sclerosis. In a similar study, Valenti et al. (2011) showed that in a
small studypopulationof non-alcoholic fatty liver patients, carotid
intima medial thickness and carotid plaque were independently
associated with increased ferritin levels.
The potentially damaging effect of iron on the heart, pancreas,
liver and other organs was made evident in part through the study
of hemochromatosis, a disorder in which excess iron is absorbed
and deposited in tissues. Patients with untreated hemochromato-
sis can exhibit diabetes, liver damage, and cardiac injury among
other symptoms (Wolff, 1993; Witte et al., 1996; Powell et al.,
1998). Mutations in HFE gene (the hemochromatosis gene) are
one cause of hemochromatosis. Using a mouse model for heredi-
tary hemochromatosis, Turoczi et al. (2003) showed an interaction
of dietary iron intake and HFE gene status (KO vs. wildtype) in
degree of ischemia/reperfusion injury to heart; HFE KO mice
showed greater ventricular dysfunction, myocardial infarct size,
and cardiomyocyte apoptosis compared to wild type mice on a
standard diet, and an even greater degree of damage in theHFEKO
mice fed a high iron diet (Turoczi et al., 2003). In human subjects,
a similar increase in cardiovascular death was observed in women
heterozygous for the HFE gene (Roest et al., 1999). However, no
association between the HFE genotype and atherosclerosis has
been found in hemochromatosis patients in spite of iron overload
status in these patients (van der et al., 2006; Engberink et al., 2010).
Valenti et al. (2011) found that the prevalence of carotid plaques
was highest in patients with hyperferritinemia independent of
HFE genotype. Although the risk of atherosclerotic heart disease
appears unrelated to HFE genotype, hemochromatosis patients
do have a higher risk of iron-related non-ischemic cardiovascular
irregularities (Gaenzer et al., 2002; Dunn et al., 2008).
Multiple mechanisms likely underlie the association of iron
with CVD. In addition to the ability of iron to promote lipid per-
oxidation, recent studies have implicated the peptide hormone
hepcidin in atherosclerosis. Hepcidin is a central regulator of iron
absorption and recycling (Ganz, 2013). Hepcidin acts by bind-
ing ferroportin, an iron efﬂux pump present in both enterocytes
and macrophages. Binding of hepcidin to ferroportin triggers
ferroportin degradation (Nemeth et al., 2004), thus inhibiting
the delivery of iron to the circulation through the enterocyte as
well as inhibiting iron recycling in macrophages. Valenti et al.
(2011) observed that serum hepcidin was independently associ-
ated with carotid plaques, suggesting that hepcidin-induced iron
accumulation may be involved in the process of atherogenesis in
subjects negative for HFE mutations. Speciﬁcally, hepcidin may
induce excessive iron trapping within macrophages, resulting in
an increase in oxidative stress, transformation into foam cells,
and ultimately to atherosclerotic vascular disease (Sullivan, 2007,
2009; Theurl et al., 2008). This hypothesis is known as the “iron
hypothesis” and was proposed by Sullivan (2009). Since hepcidin
is decreased in patients with hereditary hemochromatosis, this
model provides a potential explanation for the previous obser-
vation that atherosclerosis risk is not increased in subjects with
hereditary hemochromatosis (van der et al., 2006). However, a
recent experimental study provided evidence that hepatic hep-
cidin expression is not correlated with atherosclerosis progression
in a mouse model Kautz et al. (2013). Further, the authors
reported that increasing macrophage iron accumulation in mice
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with atherosclerosis either through a genetic mutation in the fer-
roportin gene or through parenteral iron administration failed to
increase the size of atherosclerotic lesions or lesion calciﬁcation.
The study challenged the “iron hypothesis.”
An alternative approach to the use of serum ferritin to assess the
relationship between iron andCVDhas been to assess the relation-
ship between catalytic iron and heart disease. Catalytic iron is the
iron that is not bound to transferrin or ferritin and is available to
take part in chemical reactions to produce oxidant products. This
can be measured using a bleomycin detectable iron assay (BDI;
von Bonsdorff et al., 2002). Results from such studies are equiv-
ocal. While some studies found a relation between catalytic iron
with CVDs (Rajapurkar et al., 2012), a recent study with a larger
study population failed to report any association of catalytic iron
with risk of MI and recurrent ischemic events (Steen et al., 2013).
However the study showed that in a cohort of 1701 patients with
AMIor unstable angina, catalytic ironwas associatedwith stepwise
increase in all-cause mortality (multivariate adjusted HR = 3.97,
95% CI 1.09–14.1, p = 0.036, highest quartile vs. baseline) when
followed for amedian of 10months. Although no signiﬁcant asso-
ciation of ischemic events with iron was reported, most of the
deaths were related to ischemic complications, and thus the con-
tribution of catalytic iron could not be ruled out completely. It is to
be noted that serum catalytic iron does not reﬂect the intraplaque
iron which might be a more proximal factor for vascular ischemic
injuries (Nelson et al., 1992; Castellanos et al., 2002). Unfortu-
nately, these studies did not report the relationship between serum
ferritin and outcome. It thus remains unaddressed whether or not
catalytic iron is more strongly associated than serum ferritin with
outcome.
Another approach to testing a potential link between iron and
CVDs has been the study of dietary iron intake and risk. Zhang
et al. (2012) reported that dietary intake of total iron was posi-
tively associated with deaths from strokes and CVD in a cohort of
23,083 Asian men with a multivariate hazard ratio of 1.43 (95%
CI, 1.02–2, p = 0.009) for stroke and 1.27 (95% CI, 1.01–1.58,
p = 0.023) for CVD after adjustment for other CVD risk factors;
iron intake was not associated with these outcomes in women,
however. In another large prospective study in almost 50,000
European men, there was a positive association of dietary iron,
more speciﬁcally heme iron (a form of iron that is more read-
ily absorbed by the gut than inorganic iron), with strokes in a
follow-up period of 11.7 years (Kaluza et al., 2013). Adjustments
were made for red meat consumption to rule out confounding by
other known risk factors for stroke such as N-nitroso compounds
and heterocyclic compounds (Forstermann, 2008). The associa-
tion was observed in normal weight men and not in overweight or
obese men, most likely because of decreased iron absorption due
to increased hepcidin in the chronic inﬂammatory state associated
with obesity (Greenberg and Obin, 2006). Adipocyte hepcidin
expression is known to be positively correlated with obesity (Bekri
et al., 2006). This association is still to be properly evaluated in
women.
Although the foregoing studies appear well-conducted, there
are also a number of other well-conducted studies that have
found no association of markers of body iron and risk of CVD
(Baer et al., 1994; Danesh and Appleby, 1999; Gupta et al., 2000;
Knuiman et al., 2003; Sun et al., 2008b; Friedrich et al., 2009). Dis-
cordant results among studies may in part be due to imprecision
in the surrogate markers used to measure iron status (ferritin,
total iron binding capacity, transferrin saturation, serum iron,
and dietary iron intake), which are all indirect measures of body
iron stores. Because these variables are subject to temporal and
measurement variations, there is undoubtedly exposure misclas-
siﬁcation in the subjects. This non-differential misclassiﬁcation
would reduce the ability of a study to identify a true association
should one exist. An additional potential problem, particularly in
cross-sectional studies, is that observed elevations in serum fer-
ritin may represent an effect rather than a cause of underlying
pathology.
If iron is associated with CVD, can interventions that reduce
iron reduce risk? Unfortunately, only a limited number of inter-
vention studies have been conducted, but results of these studies
are at least suggestive that modulating iron can reduce risk. In ani-
malmodels, treatmentwith deferoxamine, an iron chelator, during
ischemia improved recovery and reduced reperfusion-induced
oxygen radical formation in rabbit hearts (Williams et al., 1991).
Paraskevaidis et al. (2005) reported that deferoxamine infusion
ameliorated lipid peroxidation and improved long term outcome
in patients having coronary artery bypass surgery. In a recent ran-
domized controlled single blinded study, Zacharski et al. (2011)
showed that a lower ferritin level predicted improved outcome
and iron reduction by phlebotomy improved outcomes by pre-
venting or delaying non-fatal myocardial infarction and stroke in
young age patients with peripheral artery disease.
IRON AND METABOLIC SYNDROME AND DIABETES
Metabolic syndrome refers to a collection of risk factors that
increase the likelihood of heart disease, diabetes and stroke. They
include a large waistline, high triglyceride, low HDL cholesterol,
high blood pressure and high fasting blood sugar. The presence of
three of these ﬁve risk factors, many of which are associated with
obesity, is deﬁned as metabolic syndrome3.
Multiple studies have shown that excess body iron is associ-
ated with one or more components of metabolic syndrome (Jehn
et al., 2004; Bozzini et al., 2005; Choi et al., 2005; Gonzalez et al.,
2006; Sun et al., 2008a). To study the association of iron with
metabolic syndrome in normal individuals, a cross-sectional study
in 6044 US adults was conducted. The results showed a signiﬁcant
association of ferritin level with metabolic syndrome and insulin
resistance (IR) after excluding hemochromatosis cases and adjust-
ing for age, race/ethnicity, C-reactive protein, smoking, alcohol
intake, and BMI (Jehn et al., 2004). Other studies in western pop-
ulations showed similar associations (Jehn et al., 2004; Bozzini
et al., 2005; Gonzalez et al., 2006; Wrede et al., 2006). A positive
association of serum ferritin with the prevalence of metabolic
syndrome in a study population of 8441 people including both
sexes and from different provinces of China was recently reported
(Li et al., 2013). Mendler et al. (1999) showed that in a cohort
of patients with unexplained hepatic iron overload, IR was also
often observed. Such patients with non-alcoholic fatty liver dis-
ease also tend to have elevated ferritin levels (Valenti et al., 2003,
3http://www.nhlbi.nih.gov/health/health-topics/topics/ms/
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2006, 2007, 2010) which is now considered a feature of metabolic
syndrome (Marchesini et al., 2001, 2003; Angulo, 2002). The con-
stellation of hepatic steatosis, mild to moderate iron overload
in both hepatocytes and macrophages, increased serum ferritin
levels, and insulin resistance is commonly referred to as dys-
metabolic iron overload syndrome or DIOS (Barisani et al., 2008;
Riva et al., 2008; Datz et al., 2013). DIOS is detected in about one
third of the patients with NAFLD and MetS and may be pre-
disposing factor to the development of type 2 DM and CVDs
[Dongiovanni et al., 2011; Valenti et al., 2012; See Dongiovanni
et al. (2011) and Datz et al. (2013) for detailed discussion and
review of this topic]. Iron depletion in such patients has been
shown to improve histological liver damage and abnormal liver
function when compared to lifestyle modiﬁcation (Valenti et al.,
2014).
Similarly, many epidemiological studies have reported statisti-
cally signiﬁcant associations of body iron with diabetes, although
results from all studies are not entirely consistent. In one longi-
tudinal study of overweight/obese individuals with an impaired
glucose tolerance test, there was no association between ferritin
levels with risk of diabetes (Rajpathak et al., 2009). In another sim-
ilar study, adjustment for BMI and components of the metabolic
syndrome produced a null result (Jehn et al., 2007). However, in
a prospective study in China, a country with the largest diabetic
population in the world, an almost twofold increased risk of type 2
diabetes was observed among middle aged and elderly persons in
the highest quintile of ferritin level compared with those in lowest
after adjusting for known risk factors including high sensitivity
C reactive protein (hsCRP), BMI, γ-glutamyl transferase (GGT),
and adiponectin (Sun et al., 2013). The result was consistent with
ﬁndings from similar prospective cohort studies inCaucasian pop-
ulations (Salonen et al., 1998; Jiang et al., 2004; Forouhi et al.,
2007; Montonen et al., 2012). In the EPIC (European Prospec-
tive Investigation of Cancer)-Norfolk cohort, serum ferritin was
an important and independent predicting factor for development
of diabetes after adjustment for conventional risk factors as well as
vitamin C levels, CRP, IL6, liver function test (ALT, GGT), ﬁbrino-
gen and adiponectin (Forouhi et al., 2007). In a case cohort study
among 27,548 participants of the EPIC Postdam study in Ger-
many, the sTFR-ferritin ratio was signiﬁcantly inversely related to
the risk of type 2 diabetes, and ferritin concentration was asso-
ciated with higher risk (Montonen et al., 2012). The result was
independent of biomarkers of inﬂammation, hepatic fat, IR, and
dyslipidemia.
In evaluating these studies, a few considerations must be borne
in mind. In epidemiological studies investigating the relation
between iron and diabetes, serum ferritin is the most commonly
used indicator of body iron stores. As mentioned in the intro-
duction, the use of ferritin in assessing body iron stores has
been somewhat challenging because ferritin can be elevated in
inﬂammation, cancer, and liver disease (Wang et al., 2010). Serum
ferritin concentration can also be increased in some conditions
like obesity and metabolic syndrome which are associated risk
factors for type 2 diabetes (Lee et al., 2009). It thus becomes
difﬁcult to discernwhether the association of ferritin with diabetes
is due to other concomitant conditions or serum ferritin levels
increase as a result of diabetes (a case of reverse causation). In
addition, serum ferritin has been correlated with dyslipidemia
biomarkers (Halle et al., 1997), hepatic enzymes (Choi et al., 2005),
and negatively associated with adiponectin, an insulin sensitiz-
ing adipokine that is decreased in diabetic patients (Forouhi
et al., 2007). Thus adjustments for these components become very
important.
The exact molecular mechanism of iron-related pathology
in metabolic syndrome and diabetes is not clearly understood.
Iron is a powerful pro-oxidant and can cause cellular damage
by producing reactive oxygen species in different tissues of the
body (Andrews, 1999; Rajpathak et al., 2009). Insulin producing
pancreatic β cells have been shown to be particularly suscep-
tible to oxidative injury, in part due to decreased expression
of antioxidant enzymes such as dismutase, catalase, and glu-
tathione peroxidase (Tiedge et al., 1997). Thus iron deposition
in β cells can lead to apoptosis and consequently to decreased
insulin synthesis and secretion (Tiedge et al., 1997; Ferrannini,
2000; Cooksey et al., 2004). A recent study in a mouse model
of iron overload showed that iron deposition enhances fatty
acid oxidation and decreases glucose oxidation in skeletal mus-
cle by inhibiting pyruvate dehydrogenase (PDH) enzyme activity
thus increasing IR (Huang et al., 2011). Glucose oxidation is
decreased in adipose tissue (Merkel et al., 1988; Green et al.,
2006). Iron accumulation also results in an abnormal increase
in hepatic glucose production (Mendler et al., 1999; Ferrannini,
2000; Green et al., 2006), inappropriate hepatic insulin extrac-
tion, and affects insulin secretion in the pancreas (Niederau et al.,
1984). A recent study of 492 subjects demonstrated an associ-
ation between markers of iron metabolism, adipocyte insulin
resistance, and adiponectin (an insulin-sensitizing adipokine),
consistent with a model in which iron contributes to T2DM by
inducing insulin resistance in adipocytes (Wlazlo et al., 2013).
Consistent with this model, mice fed a high iron diet exhibited
an accumulation of iron within adipocytes and altered tran-
scription of adipokines involved in glycemic control (Gabrielsen
et al., 2012; Dongiovanni et al., 2013). In particular, iron
downregulated adiponectin (an adipokine with insulin sensi-
tizing action; Gabrielsen et al., 2012) and increased resistin
(an adipokine with hyperglycemic action; Dongiovanni et al.,
2013).
The association of dietary iron and diabetes has also been
examined. Iron in the diet exists as heme (organic) and non-
heme (inorganic) forms. Some studies have shown that the risk
of diabetes can be increased by heme iron in the diet (Jiang et al.,
2004; Lee et al., 2004; Rajpathak et al., 2006). Most of these studies
were conducted in a healthy US population. In Asian popula-
tions, a similar association was reported in a cross sectional study
of 2997 Chinese people (Luan de et al., 2008). Consistent results
were obtained in an observational cohort of Mediterranean people
(Fernandez-Cao et al., 2013). Two recentmeta-analyses concluded
that higher heme iron poses higher risk of type 2 diabetes (Bao
et al., 2012; Zhao et al., 2012). One of the studies reported that
there was no signiﬁcant association with total iron, non-heme
iron or iron supplements in the diet (Bao et al., 2012). How-
ever, these studies did not separate heme iron per se from other
components of red meat. Red meat bears a high correlation with
heme iron and has been shown to be associated with the risk of
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FIGURE 1 | Model showing iron retention in macrophages promotes arterial plaque destabilization (Sullivan, 2007;Theurl et al., 2008).
FIGURE 2 | Model showing multiple mechanisms through which iron can lead to insulin resistance and insufficiency (Merkel et al., 1988;Tiedge et al.,
1997; Mendler et al., 1999; Ferrannini, 2000; Cooksey et al., 2004; Green et al., 2006; Huang et al., 2011).
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type 2 diabetes (Pan et al., 2011). Therefore confounding by other
components from red meat cannot be ruled out with certainty.
Screening for HFE mutation was not conducted in these studies,
and hence a contribution of genetic interaction cannot be ruled
out either.
Despite the limitations of epidemiological studies, intervention
studies support the associationbetween excess iron,metabolic syn-
drome and diabetes. Iron reduction by phlebotomy and chelation
therapy produced an improvement in glucose tolerance not only in
patients with hemochromatosis (Dymock et al., 1972; Inoue et al.,
1997), but also in healthy donors. Houschyar et al. (2012) reported
that reduction of body iron stores through phlebotomy had ther-
apeutic effects in metabolic syndrome patients, including lowered
blood pressure and improvement in glycemic control and cardio-
vascular risks. Fernandez-Real et al. (2002) found that bloodletting
in high ferritin type 2 diabetes patients resulted in decrease in
glycated hemoglobin and also improved insulin secretion and
sensitivity.
CONCLUSION
Epidemiological studies provide evidence that elevated iron stores
are a risk factor for developing cardiovascular and metabolic
abnormalities. Such results have been veriﬁed in diverse ethnic and
geographic populations. Although mechanistic insights have been
limited, iron-dependent pathophysiological pathways involved in
these two conditions may exhibit some differences. In diabetes
and metabolic syndrome, iron may contribute to risk following
deposition in the liver, pancreas, and skeletal muscle, where it can
enhance oxidative damage and contribute to insulin deﬁciency and
resistance. In CVD, iron within macrophages and foam cells pre-
disposes to the formationof atherosclerotic plaques. Hepcidinmay
promote plaque destabilization by preventing iron export from the
intralesional macrophages leading to ischemic events. Although
additional mechanisms are likely involved, Figures 1 and 2 illus-
trate some pathways through which excess iron can increase risk
of CVD, metabolic syndrome, and diabetes.
Regarding iron in the diet, there is still insufﬁcient data to
formulate guidelines on dietary iron restrictions in the at-risk or
general population. This is primarily because dietary iron exists in
two very different forms – heme and non-heme iron. Study ﬁnd-
ings aremore inclined toward the association of heme iron (mainly
frommeat) and disease risk rather than non-heme iron. Although
some studies have attempted to assess whether iron supplemen-
tation is linked to disease risk, particularly diabetes in women,
the results have been inconsistent (Rajpathak et al., 2006; Bo et al.,
2009; Chan et al., 2009).
Further research is required to identifymore predictors of body
iron stores that may help in reducing the risk of cardiovascular or
metabolic disease. Experiments are needed to unravel the under-
lying biological mechanism of this association. Additionally, more
randomized controlled studies are warranted to evaluate the clini-
cal outcome of patients placed on iron restricted diets or subjected
to iron depletion therapy so that therapeutic recommendations
can be made.
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